Cytokine Storm: A Suicidal Immune Response to Novel Corona Virus

Gohil, Jignakumari J.; Gohil, Chiragkumar J.

doi:10.34257/gjmrbvol21is1pg31

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nutlins mimic the three main amino acid residues on p53 (i, i+4, i+7), involved in its interaction with MDM2. 16 Hence, it shows 3 pocket binding. And inhibit the p53-MDM2 interaction.…”

Section: Non α-Helix Mimetics (Functional Mimetics)mentioning

confidence: 99%

Chemical classification of MDM2 inhibitors

Gohil

Noolvi²,

Patel³

et al. 2021

IJPCA

View full text Add to dashboard Cite

MDM2 inhibitors class of anti-neoplastic drugs has been evolve after the successful discovery of the nutlins and other potent inhibitors. MDM2 inhibitors can specifically target the tumour cells in the body, by selectively reactivating the inhibited p53 function in the tumour cells.None of the compound of this class has been entered into the market till date, all are under clinical trials. Hence, various researcher classifies them according to their p53 topology mimetic property and as per their peptide type or non-peptide type.Synthetic peptide type of inhibitors can mimic the conformation of p53 helix. Whereas, small organic molecule (non-peptide) type of MDM2 inhibitors have been further subdivided as Non α-helix mimetics (small molecule inhibitors) and α-helix mimetics. In a line with synthetic inhibitors, many potent MDM2 inhibitors are derived from the natural origin (marine, fungus). Therefore, keeping in a view of all these characteristics, here we have classified them as per best of our knowledge.

show abstract

“…Nutlins mimic the three main amino acid residues on p53 (i, i+4, i+7), involved in its interaction with MDM2. 16 Hence, it shows 3 pocket binding. And inhibit the p53-MDM2 interaction.…”

Section: Non α-Helix Mimetics (Functional Mimetics)mentioning

confidence: 99%

Chemical classification of MDM2 inhibitors

Gohil

Noolvi²,

Patel³

et al. 2021

IJPCA

View full text Add to dashboard Cite

show abstract

“…High binding affinity represents the tight binding with target and strong inhibitors of the MDM2 protein. Hence, good binding affinity inhibitors can easily reactivate the p53 function and trigger the p53 dependent apoptosis in the cancer cells 11 .…”

Section: Design Approachesmentioning

confidence: 99%

Review of Design Approaches and Clinical Progress of Mdm2 Inhibitors

Gohil¹,

Noolvi²,

Patel³

et al. 2021

Int. Res. J. Pharm.

Self Cite

View full text Add to dashboard Cite

Activation of the oncogenes and inhibition of the apoptotic function of the p53 protein is a gateway for the cancer genesis. Interaction of the MDM2 protein with p53 protein is responsible for the inhibition of the p53 function. Inhibiting the p53-MDM2 interaction by drug will lead to the p53 release in the cancer cells. And can restart the apoptosis in the cancer cell. Computational methods successfully used for the design and development of the new, potent MDM2 inhibitors. Researchers and pharma companies used rational approach like target-based drug design or ligand-based drug design to develop the novel MDM2 inhibitors. The number of MDM2 inhibitors, has been designed by the computer-aided drug design and in-silico studies. In clinical studies, MDM2 inhibitors are led by RG7112. RG7112 completed its phase-1 trials in 2016, and recently it is under phase-2 trials. Along with RG7112, the number of potent MDM2 inhibitors entered the clinical trials successfully. It indicates the successful development of this class (MDM2 inhibitors). MDM2 inhibitors were found very effective in various studies for the treatment of various kinds of cancers. They have good selectivity for the tumor cells over the normal cells. It induced the dose dependent cell cycle arrest only; in the normal cells. In studies, MDM2 inhibitors successfully detached the p53 protein from the MDM2 protein. And restart the cell-killing function of the p53 protein in the cancer cells. Hence, MDM2 inhibitors can selectively kill the cancer cells over the normal cells.

show abstract

“…16 The conception of XDR-TB was first introduced at the Centers for Disease Control and Prevention (CDC) in March 2005. 17 Shortly thereafter, the data on resistance to second line drugs (SLDs) were reported during an pandemic outbreak at KwaZulu-Natal,South Africa, resulting in shocking death among TB cases co-infected with HIV in February 2006. 18 The global emergence of XDR-TB has raised the concern that the current existence of mostly drug susceptible TB will be replaced with a complicated form of TB with limited treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

Antibiotic drug resistance TB in India

Gohil

Patel²,

Gohil³

2022

IJPCA

Self Cite

View full text Add to dashboard Cite

Tuberculosis is a disease caused by bacteria spread from person to person through air. TB usually affects the lungs, but it can also affect other parts of the body, such as brain or kidney. Global surveillance has shown that drug resistant TB is widespread and is now a treat to tuberculosis control programs in many countries. This review describes treatment of tuberculosis and the drug resistance problem in India.

show abstract

Cytokine Storm: A Suicidal Immune Response to Novel Corona Virus

Cited by 3 publications

References 23 publications

Chemical classification of MDM2 inhibitors

Chemical classification of MDM2 inhibitors

Review of Design Approaches and Clinical Progress of Mdm2 Inhibitors

Antibiotic drug resistance TB in India

Contact Info

Product

Resources

About